TABLE 1.
Tissue culture and PCR results for control and experimental infection groups
| Experimental group | Dog no. | Tissue culture result/PCR result at the following timesa:
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infection period
|
Posttreatment period (PID)
|
Postchallenge period
|
|||||||||||
| 7 | 14 | 21 | 29 | 49 | 62 | 76 | 90 | 111 | 118 | 133 | 148 | ||
| Uninoculated control group | 151 | −/− | −/− | −/− | −/− | −/− | −/− | −/− | */− | −/− | −/− | −/− | −/− |
| 161 | − | − | − | −/− | −/− | −/− | −/− | */− | − | − | − | − | |
| 162 | − | −/− | − | −/− | −/− | −/− | */− | */− | − | − | − | − | |
| 164 | − | − | − | −/− | −/− | */− | */− | */− | − | − | − | − | |
| Infected control group | 150 | −/+ | −/+ | +/+ | +/+ | +/+ | −/− | */− | */− | − | − | − | − |
| 152 | +/− | +/− | +/+ | +/+ | −/+ | −/+ | */− | */− | − | * | + | − | |
| 153 | −/+ | +/+ | +/+ | +/− | −/− | +/+ | −/− | */+ | +/+ | −/+ | −/+ | −/+ | |
| 163 | − | +/+ | +/+ | − | −/+ | −/− | −/− | */− | − | − | − | − | |
| Homologous challenge group | 155 | − | + | +/− | +/+ | −/− | −/− | */− | */− | + | − | − | − |
| 156 | − | + | +/+ | */+ | −/− | −/− | */− | */− | − | − | + | − | |
| 157 | − | + | + | +/+ | −/− | −/− | −/− | */− | + | + | + | + | |
| 158 | − | + | + | +/+ | −/− | −/− | */− | */− | − | + | − | − | |
| Heterologous challenge group | 149 | + | −/− | +/− | −/− | −/− | −/− | −/− | */− | − | + | + | − |
| 154 | + | +/+ | +/+ | +/+ | −/− | −/− | */− | */− | + | + | + | + | |
| 159 | − | +/+ | + | −/− | −/− | −/− | −/− | */− | − | + | − | − | |
| 160 | − | +/+ | + | − | −/− | −/− | */− | */− | + | − | − | − | |
a
If only a single result is provided, the results reflect tissue culture findings only. Tissue culture supernatants were examined at 4, 6, and 8 weeks after cultures were established. Positive (+) results reflect detection of organisms on at least two occasions. Negative (−) results indicate that no organisms were observed. Asterisk indicate that cultures failed to persist for at least 6 weeks; therefore, the results were considered inconclusive. For dogs in the homologous challenge and heterologous challenge groups, treatment was from PIDs 31 to 44 and the challenge inoculation was given on PID 90.